Clindacyl 300 mg Tablets for Dogs

Country: Ireland

Bahasa: Inggeris

Sumber: HPRA (Health Products Regulatory Authority)

Bahan aktif:

Clindamycin (as clindamycin hydrochloride)

Boleh didapati daripada:

Chanelle Animal Health Ltd.

Kod ATC:

QJ01FF01

INN (Nama Antarabangsa):

Clindamycin (as clindamycin hydrochloride)

Dos:

300 mg/tablet

Borang farmaseutikal:

Tablet

Jenis preskripsi:

POM: Prescription Only Medicine as defined in relevant national legislation

Kumpulan terapeutik:

Dogs

Kawasan terapeutik:

clindamycin

Tanda-tanda terapeutik:

Antibacterial

Status kebenaran:

Authorised

Tarikh kebenaran:

2008-07-30

Ciri produk

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Clindacyl 300 mg Tablets for Dogs.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
3 PHARMACEUTICAL FORM
Tablet
An oblong white to off white tablet with a break line on one side.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of:
Infected wounds, abscesses and oral cavity/dental infections caused by
or associated with clindamycin-sensitive species
of:
_Staphylococcus_ spp.
_Streptococcus_ spp.
_Bacteroides_ spp.
_Fusobacterium necrophorum_
_Clostridium perfringens_
Osteomyelitis
_Staphylococcus aureus_
4.3 CONTRAINDICATIONS
Do not use in cases of known hypersensitivity to lincosamides.
Do not administer to rabbits, hamsters, guinea pigs, chinchillas,
horses or ruminants because ingestion of clindamycin
by these species may result in severe gastro-intestinal disturbance.
ACTIVE SUBSTANCE:
Clindamycin (as Clindamycin Hydrochloride) 300 mg
EXCIPIENTS:
For the full list of excipients, see section 6.1
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_1_
_0_
_/_
_1_
_1_
_/_
_2_
_0_
_1_
_6_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_4_
_8_
_7_
_0_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None known.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
During prolonged therapy of one month or greater, periodic liver and
kidney function tests and blood counts sho